Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirikizumab in active Crohn's Disease
NCT02891226Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Mirikizumab with Placebo (2 arms). Primary endpoint: Percentage of Participants Achieving Endoscopic Response at 12 weeks. Started Dec 2016; status: completed.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02891226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891226.